Literature DB >> 8018783

Striatal dopamine receptor binding in epileptic psychoses.

H A Ring1, M R Trimble, D C Costa, J Moriarty, N P Verhoeff, P J Ell.   

Abstract

In order to study the nature of dopaminergic activity in epileptic psychoses we investigated striatal dopamine receptor binding in 14 patients with epilepsy. Seven of the patients were acutely psychotic when studied, having recently developed a periictal schizophreniform psychosis. The remaining patients were not psychotic. All patients were scanned using single photon emission tomography (SPET) with 123I-IBZM, a specific dopamine D2 receptor ligand. A region of interest analysis was performed. Comparison of mean basal ganglia to occipital cortex activity ratios in the two groups demonstrated significantly reduced specific binding of 123I-IBZM to striatal D2 receptors in the psychotic patients compared to those without psychosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018783     DOI: 10.1016/0006-3223(94)90003-5

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  4 in total

Review 1.  Psychosis and seizure disorder: challenges in diagnosis and treatment.

Authors:  Kamalika Roy; Richard Balon; Varma Penumetcha; B Harrison Levine
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

Review 2.  Alternating and postictal psychoses: review and a unifying hypothesis.

Authors:  Perminder S Sachdev
Journal:  Schizophr Bull       Date:  2007-03-03       Impact factor: 9.306

Review 3.  Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review.

Authors:  Martin J Brodie; Frank Besag; Alan B Ettinger; Marco Mula; Gabriella Gobbi; Stefano Comai; Albert P Aldenkamp; Bernhard J Steinhoff
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

4.  Reduced D2/D3 Receptor Binding of Extrastriatal and Striatal Regions in Temporal Lobe Epilepsy.

Authors:  Viviane E Bernedo Paredes; Hans-Georg Buchholz; Martin Gartenschläger; Markus Breimhorst; Mathias Schreckenberger; Konrad J Werhahn
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.